Status and phase
Conditions
Treatments
About
The purpose of this study is to evaluate the side effects and effectiveness of giving standard paclitaxel chemotherapy in doses based on actual body surface area in combination with standard dosed carboplatin chemotherapy for overweight women.
Full description
Primary Objective The primary objective is to prospectively evaluate the Relative Dose Intensity (RDI) and toxicity of weight-based dose dense weekly paclitaxel and carboplatin in overweight patients with a BSA > 2.0 compared to the Japanese Gynecologic Oncology Group trial (JGOG 2016) during 6 - 9 cycles of chemotherapy.
Secondary Objective(s) The secondary objective is to evaluate progression-free survival in this patient population.
Study Design This is a descriptive study to determine what the relative dose intensity of patients who are overweight with a BSA of greater than 2.0 can achieve.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patients with a histologically confirmed or presumed diagnosis of gynecologic malignancy for whom chemotherapy with paclitaxel and carboplatin is planned.
Body Surface area >2.0
Patients must have adequate:
Renal function: Creatinine <1.5 x Institutional upper limits of normal (ULN)
Bone marrow function:
Hepatic function:
Neurologic function:
Patients must have a Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2.
Patients must be entered within 12 weeks of diagnosis.
Subjects must have the ability to understand and the willingness to sign a written informed consent document.
Exclusion criteria
Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis. Prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease.
Patients who have received prior chemotherapy.
Patients with acute hepatitis or active infection that requires parenteral antibiotics.
Patients with clinically significant cardiovascular disease. This includes:
Patients who are pregnant or nursing.
Patients with medical history or conditions not otherwise previously specified which in the opinion of the investigator should exclude participation in this study.
Patients with known allergy to cremophor or polysorbate 80.
Primary purpose
Allocation
Interventional model
Masking
3 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal